期刊
CANCER TREATMENT REVIEWS
卷 34, 期 1, 页码 49-60出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2007.09.001
关键词
gemtuzumab ozogamicin; acute myeloid leukemia; monoclonal antibodies; immunoconjugate; immunotoxin
类别
Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) Linked to N-acetyl-caticheamicin 1,2-dimethyl hydrazine dichtoride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AML) in patients over the age of 60 years who are unfit for conventional cytotoxic therapy. In this setting, it produces a complete response (CR) rate of 13%, with another 13% achieving CR with inadequate ptatelet recovery (CRp). The most common adverse effects associated with GO are infusion-related reactions and myelosuppression. GO monotherapy at the dose of 9 mg/m(2) is complicated with hepatic veno-occlusive disease in approximately 5% of cases, particularly prior to or following stem cell transplantation. Attenuated doses of GO or fractionated doses appear to be equally effective and better tolerated. GO has shown remarkable activity in acute promyelocytic leukemia, particularly for the elimination of minimal residual. disease. Combinations of GO with chemotherapy as induction or post-remission therapy are promising, and phase III trials are ongoing. (c) 2007 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据